News Release Details

- Acumen Pharmaceuticals recognized for ACU193, the first clinical-stage monoclonal antibody to selectively target toxic soluble amyloid beta oligomers (AβOs), for treatment of early Alzheimer’s disease
- Annual BioTech Breakthrough Award is devoted to honoring excellence in life science and biotechnology solutions, services and companies

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IND., November 8, 2023 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced it has been awarded the prestigious “Monoclonal Antibody Solution of the Year”  by the BioTech Breakthrough Awards program, organized by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Acumen was recognized for ACU193, a differentiated, next-generation monoclonal antibody that selectively targets toxic soluble AβOs, which decades of scientific evidence implicate as a highly neurotoxic species of Aβ and an early and persistent trigger of AD. While there has been significant progress in AD drug development in the last few years – giving hope to many patients, their families and clinicians – there remains a need to improve upon existing treatments with next-generation, increasingly targeted therapeutic options that offer differentiated safety and efficacy profiles.

“Winning the ‘Monoclonal Antibody Solution of the Year’ award is a testament to Acumen’s commitment to developing a targeted, next-generation therapy for Alzheimer’s disease, with the potential to offer differentiated safety and efficacy compared to existing AD therapies,” said Daniel O’Connell, President and Chief Executive Officer of Acumen. “This recognition affirms our dedication to advancing Alzheimer’s research. In a world where AD is on the rise, our work has never been more critical, and we strive to develop ACU193 as an innovative treatment that preserves quality time for all people impacted by Alzheimer’s.”

Positive results from the Phase 1 INTERCEPT-AD trial evaluating ACU193 for treatment of early AD, demonstrated rapid, dose-related, direct target engagement of AβOs in a dose proportional manner, statistically significant amyloid plaque reduction within higher dose cohorts, and had low overall levels of ARIA-E. Acumen will further evaluate ACU193 in a Phase 2/3 trial, with the Phase 2 portion planned to commence in the first half of 2024.

About ACU193
ACU193 is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble AβOs, which Acumen believes are the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, ACU193 aims to directly address a growing body of evidence indicating that soluble AβOs are a primary underlying cause of the neurodegenerative process in Alzheimer’s disease. ACU193 has been granted Fast Track designation for the treatment of early Alzheimer’s disease by the U.S. Food and Drug Administration. 

About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN, and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive topline results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

About BioTech Breakthrough Awards
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen’s business, and the therapeutic potential of Acumen’s product candidate, ACU193, including against other antibodies, and the anticipated timeline for reporting topline data.  These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC, including Acumen’s most recent Quarterly Report on Form 10-Q. Copies of these and other documents are available from Acumen.  Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com